Published in Lancet Respir Med on September 10, 2013
Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations | NCT02606487
CFTR Modulators for the Treatment of Cystic Fibrosis. P T (2014) 0.81
Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis. BMJ Open Respir Res (2014) 0.81
Targeted therapies to improve CFTR function in cystic fibrosis. Genome Med (2015) 0.79
Current Progress in Therapeutic Gene Editing for Monogenic Diseases. Mol Ther (2016) 0.78
The evolution of blood-spot newborn screening. Transl Pediatr (2014) 0.78
Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis. PLoS One (2015) 0.77
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. Clin Pharmacol (2016) 0.77
Novel outcome measures for clinical trials in cystic fibrosis. Pediatr Pulmonol (2014) 0.75
Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report. BMC Pulm Med (2015) 0.75
Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis. Hippokratia (2015) 0.75
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor. Expert Opin Orphan Drugs (2016) 0.75
Paediatrics: messages from Munich. ERJ Open Res (2015) 0.75
Mutation-specific therapy in cystic fibrosis: the earlier, the better. Lancet Respir Med (2013) 0.75
Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Thorax (2016) 0.75
Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ Open Respir Res (2017) 0.75
Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms. Drugs R D (2016) 0.75
PharmGKB summary: very important pharmacogene information for CFTR. Pharmacogenet Genomics (2015) 0.75
Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med (2016) 0.75
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Front Pharmacol (2016) 0.75
Closed circuit rebreathing to achieve inert gas wash-in for multiple breath wash-out. ERJ Open Res (2016) 0.75
PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics (2017) 0.75
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years With Cystic Fibrosis Homozygous for F508del-CFTR. Am J Respir Crit Care Med (2016) 0.75
Lung Clearance Index (LCI) is Stable in Most Primary Ciliary Dyskinesia (PCD) Patients Managed in a Specialist Centre: a Pilot Study. Lung (2017) 0.75
Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Am J Respir Crit Care Med (2016) 0.75